Effect of obesity on the effectiveness of hormonal contraceptives: an individual participant data meta-analysis

Abstract

ObjectiveThe objective of this investigation was to assess the potential effect of obesity on the effectiveness of hormonal contraceptives (HCs). Study DesignA meta-analysis was conducted using individual participant data directly from the Phase 3 clinical trials of combination oral contraceptives (COCs) rather than extracting summary data from literature. Trials selected were reviewed by the US Food and Drug Administration (FDA) between 2000 and 2012, conducted in North America, had more than six 28-day cycle equivalents of exposure, and had readily retrievable participant-level data. Contraceptive effectiveness was measured by the Pearl Index (PI: the number of pregnancies per 100 woman-years) in women aged 18–35 at risk of unintended pregnancy. The incidence rate ratio (IRR), a ratio of PIs for obese women (defined as body mass index [BMI] ≥30 kg/m2) compared to non-obese women (BMI <30 kg/m2) was calculated. A Cox proportional-hazard regression model with fixed and random-effects were used to estimate hazard ratios (HRs) for unintended pregnancy in obese women compared to non-obese women. ResultsSeven clinical trials with COCs (N=14,024: 2707 obese and 11,317 non-obese women) met the inclusion criteria for the meta-analysis. The PI for each trial varied: 2.05–5.08 for obese and 1.84–3.80 for non-obese women. The pooled PI estimated using direct weighted average method was 3.14 (95% CI: 2.33–4.22) for obese and 2.53 (95% CI: 1.88–3.41) for non-obese women. The pooled IRRs estimated using direct weighted average and Mantel–Haenszel adjustment methods were comparable: 1.37 (95% CI: 1.02–1.84) and 1.43 (95% CI: 1.07–1.92), respectively. The overall HR of 1.44 (95% CI: 1.06–1.95; p=.018) in the meta-analysis suggested a 44% higher pregnancy rate during COC use for obese women after adjusting for age and race. Implications StatementObesity may increase the risk of unintended pregnancy in women using COCs; more data on obese women from ongoing and future Phase 3 clinical trials are necessary to allow further evaluation of this topic. ConclusionsResults of this meta-analysis suggest that obese women may have a higher pregnancy rate during COC use compared to non-obese women. Future analysis should assess differences in pharmacodynamics or compliance that could potentially account for the observed difference in unintended pregnancy rates.